ASX-Dividend-Report-Banner

Broncus Medical (02216.HK) Announces Annual Results for 2023

March 29, 2024 01:32 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Broncus Medical (02216.HK) Announces Annual Results for 2023
Image source: Kalkine Media

The treatment products R&D continue to lead, and product sales are steadily advancing.

HANGZHOU, China, March 28, 2024 /PRNewswire/ -- On March 28, 2024, Broncus Medical (02216.HK) (the "Company" or "we" ) announced annual results for FY 2023.

In 2023, Broncus Medical earned product sales of US$12.41 million, an increase of 32% compared to the previous year. Of which, total revenue from Mainland China was US$8.62 million with a significant increase of 48%.

 (i) In terms of clinical and product R&D:

We have completed the follow-up visit to the pivotal clinical trial of Zhiheng RF-II in 2023. The product is the world's first transbronchial interventional treatment product for lung cancer. The results of the clinical trial showed safety and efficacy of RF-II in the treatment of lung cancer in clinical use. And the study data is also used for the license applications for NMPA medical devices.

For the TLD Radiofrequency Ablation System, an innovative device for the treatment of acute exacerbation of COPD, we completed the enrollment of over 40 patients at more than 20 trial sites in the pre-marketing clinical trials in 2023. 

(ii) In terms of market access:

In 2023, the domestic version of InterVapor®, domestic version of Lungpoint and BroncTru™, a disposable transbronchoscopic puncture dilatation catheter, obtained NMPA registration certificates.

For global market, InterVapor® was successively approved in Thailand, Chinese Taiwan, Malaysia and Indonesia during the period.

(iii) In terms of commercialization:

In Mainland China, InterVapor® for COPD has been commercialized in more than 20 hospitals. About 100 hospitals have been exposed to the technology with local medical insurance coverage gradually being implemented.

For our navigation products, according to public information, the market share in Mainland China reached 40% in 2023.

For consumable products, such as BroncTru™, the disposable transbronchoscopic puncture dilatation catheter, has been applied in multi-scenarios in diagnosis and treatment of lung diseases.

In the future, we will continue to make efforts to product pricing, cost control and commercialisation to realise a positive growth in product sales.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.